Temasek Holdings Private Ltd Lowers Holdings in BioNTech SE Sponsored ADR $BNTX

Temasek Holdings Private Ltd lowered its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 16.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,506,027 shares of the company’s stock after selling 301,205 shares during the quarter. BioNTech comprises about 0.6% of Temasek Holdings Private Ltd’s holdings, making the stock its 26th largest position. Temasek Holdings Private Ltd owned 0.63% of BioNTech worth $160,347,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Baader Bank Aktiengesellschaft raised its stake in BioNTech by 6.3% during the second quarter. Baader Bank Aktiengesellschaft now owns 151,862 shares of the company’s stock worth $16,032,000 after purchasing an additional 9,040 shares during the period. Shell Asset Management Co. raised its position in shares of BioNTech by 15.3% in the 2nd quarter. Shell Asset Management Co. now owns 40,610 shares of the company’s stock worth $4,324,000 after buying an additional 5,398 shares during the period. Swedbank AB purchased a new position in shares of BioNTech in the 1st quarter worth $3,415,000. Millennium Management LLC boosted its holdings in BioNTech by 252.5% in the first quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock valued at $49,625,000 after acquiring an additional 390,360 shares during the last quarter. Finally, Allianz SE grew its position in BioNTech by 635.0% during the second quarter. Allianz SE now owns 5,880 shares of the company’s stock valued at $626,000 after acquiring an additional 5,080 shares during the period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Trading Up 0.3%

Shares of NASDAQ:BNTX opened at $96.25 on Monday. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $102.85 and its 200 day moving average price is $105.19. The company has a market cap of $21.67 billion, a PE ratio of -36.60 and a beta of 1.30. BioNTech SE Sponsored ADR has a fifty-two week low of $81.20 and a fifty-two week high of $129.27.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). The business had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The company’s revenue was up 22.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.81 EPS. Sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. HC Wainwright lifted their price objective on BioNTech from $136.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. Morgan Stanley reissued an “overweight” rating and issued a $134.00 price target on shares of BioNTech in a report on Monday, November 3rd. Cowen restated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Finally, Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research note on Tuesday, November 25th. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.42.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.